RCC
MCID: RNL014
MIFTS: 82

Renal Cell Carcinoma (RCC) malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Renal Cell Carcinoma

Aliases & Descriptions for Renal Cell Carcinoma:

Name: Renal Cell Carcinoma 54 38 12 50 24 66 29 14 69
Adenocarcinoma of Kidney 12 50 24 66
Hereditary Clear Cell Renal Cell Carcinoma 56 69
Renal Carcinoma, Chromophobe, Somatic 54 13
Renal Cell Carcinoma Non-Papillary 66 29
Nonpapillary Renal Cell Carcinoma 12 14
Hypernephroma 12 66
Rcc 12 66
Hereditary Clear Cell Renal Cell Adenocarcinoma 56
Renal Cell Carcinoma, Clear Cell, Somatic 54
Conventional Renal Cell Carcinoma 69
Renal Cell Carcinoma, Nonpapillary 54
Conventional Renal Cell Carcinoma 66
Renal Cell Carcinoma, Somatic 54
Common Renal Cell Carcinoma 66
Clear Cell Renal Carcinoma 66
Renal Cell Adenocarcinoma 50
Carcinoma, Renal Cell 42
Carcinoma Renal Cell 52
Ccrcc 66
Crcc 66

Characteristics:

Orphanet epidemiological data:

56

HPO:

32
renal cell carcinoma:
Inheritance sporadic


Classifications:

Orphanet: 56  
Rare renal diseases


External Ids:

OMIM 54 144700
Disease Ontology 12 DOID:0050387 DOID:4450
MeSH 42 D002292
NCIt 47 C9385
Orphanet 56 ORPHA422526
ICD10 via Orphanet 34 C64
UMLS 69 C0007134

Summaries for Renal Cell Carcinoma

OMIM : 54 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant... (144700) more...

MalaCards based summary : Renal Cell Carcinoma, also known as adenocarcinoma of kidney, is related to sarcomatoid renal cell carcinoma and renal clear cell carcinoma, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma is RNF139 (Ring Finger Protein 139), and among its related pathways/superpathways are Pathways in cancer and Translational Control. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

Novus Biologicals : 53 Renal cell carcinoma originates in the proximal renal tube and is the most common form of kidney cancer. Renal cell carcinoma is resistant to radiation therapy and chemotherapy, however some cases respond to immunotherapy. Interleukin-2 has produced remission in some patients, as has functional restoration of the VHL gene.

UniProtKB/Swiss-Prot : 66 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 71 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
id Related Disease Score Top Affiliating Genes
1 sarcomatoid renal cell carcinoma 33.9 CA9 FHIT HIF1A VEGFA VHL
2 renal clear cell carcinoma 33.2 DIRC2 FH FHIT FLCN MET RNF139
3 renal cell carcinoma, papillary 12.6
4 clear cell renal cell carcinoma 12.4
5 chromophobe renal cell carcinoma 12.4
6 clear cell papillary renal cell carcinoma 12.3
7 tubulocystic renal cell carcinoma 12.2
8 hereditary renal cell carcinoma 12.1
9 chromophil renal cell carcinoma 12.0
10 eosinophilic variant of chromophobe renal cell carcinoma 12.0
11 renal cell carcinoma 4 12.0
12 acquired cystic disease-associated renal cell carcinoma 11.9
13 multilocular clear cell renal cell carcinoma 11.9
14 mucinous tubular and spindle renal cell carcinoma 11.9
15 hereditary conventional renal cell carcinoma 11.9
16 renal cell carcinoma associated with neuroblastoma 11.9
17 leiomyomatosis and renal cell cancer 11.8
18 classic variant of chromophobe renal cell carcinoma 11.8
19 von hippel-lindau syndrome 11.5
20 collecting duct carcinoma 11.4
21 renal oncocytoma 11.2
22 kidney cancer 11.2
23 metanephric adenoma 11.1
24 varicocele 11.1
25 birt-hogg-dube syndrome 11.1
26 childhood kidney cell carcinoma 11.0
27 melanoma, cutaneous malignant 8 11.0
28 multilocular cystic clear cell renal cell neoplasm of low malignant potential 11.0
29 tuberous sclerosis-1 10.8
30 cowden syndrome 4 10.8
31 cowden syndrome 1 10.8
32 tumor predisposition syndrome 10.8
33 cowden syndrome 7 10.8
34 cowden syndrome 3 10.8
35 cowden syndrome 2 10.8
36 cowden syndrome 5 10.8
37 cowden syndrome 6 10.8
38 thyroid carcinoma, papillary, with papillary renal neoplasia 10.5 CA9 FH FLCN MET PRCC TFE3
39 cleft palate cardiac defect ectrodactyly 10.5 CA9 EPAS1 FLCN HIF1A MET OGG1
40 endotheliitis 10.5
41 central nervous system leiomyosarcoma 10.5 CA9 EPAS1 HIF1A VEGFA VHL
42 ovarian brenner tumor 10.5 CA9 EPAS1 FH FHIT FLCN HIF1A
43 rectum kaposi's sarcoma 10.5 FH FLCN HIF1A MET
44 complement deficiency 10.5 FH FLCN MET
45 mini stroke 10.5 CA9 EPAS1 HIF1A VEGFA VHL
46 erythrocytosis, familial, 2 10.5 HIF1A MET VEGFA VHL
47 gtp cyclohydrolase 1-deficient dopa-responsive dystonia 10.5 FH HIF1A VHL
48 generalized eruptive keratoacanthoma 10.5 CA9 TFE3 VHL
49 atrioventricular septal defect 2 10.5 EPAS1 HIF1A VHL
50 neuropathy with hearing impairment 10.5 TFE3 VEGFA VHL

Graphical network of the top 20 diseases related to Renal Cell Carcinoma:



Diseases related to Renal Cell Carcinoma

Symptoms & Phenotypes for Renal Cell Carcinoma

Clinical features from OMIM:

144700

Human phenotypes related to Renal Cell Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 32 HP:0005584

UMLS symptoms related to Renal Cell Carcinoma:


flank pain

MGI Mouse Phenotypes related to Renal Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 FHIT FLCN HIF1A HNF1A HNF1B IL2
2 immune system MP:0005387 10.15 CA9 EPAS1 FHIT FLCN HIF1A HNF1B
3 hematopoietic system MP:0005397 10.13 CA9 EPAS1 FHIT FLCN HIF1A IL2
4 mortality/aging MP:0010768 10.1 HNF1A HNF1B IL2 MET OGG1 TFE3
5 digestive/alimentary MP:0005381 10.06 MET VEGFA VHL CA9 FHIT HIF1A
6 liver/biliary system MP:0005370 9.97 OGG1 VEGFA VHL EPAS1 HIF1A HNF1A
7 muscle MP:0005369 9.7 EPAS1 HIF1A HNF1A HNF1B MET VEGFA
8 neoplasm MP:0002006 9.56 FHIT FLCN HIF1A IL2 MET OGG1
9 renal/urinary system MP:0005367 9.23 FH FLCN HIF1A HNF1A HNF1B MET

Drugs & Therapeutics for Renal Cell Carcinoma

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
2
Avastin 17 46 BEVACIZUMAB Genentech Approved July 2009
3
Inlyta 17 46 AXITINIB Pfizer Approved January 2012
4
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005
5
Proleukin 17 46 ALDESLEUKIN Chiron Approved January 1998
6
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
7
Torisel 17 46 TEMSIROLIMUS Wyeth Approved May 2007
8
Votrient 17 46 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline Approved April 2012/ Approved October of 2009

Drugs for Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 578)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 216974-75-3
4
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
7
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
8
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
9
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
10
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
11
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
12
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
13
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
14
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
15
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
16
Zoledronic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 118072-93-8 68740
17
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
19
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
20
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
21
Nicotine Approved Phase 4 54-11-5 942 89594
22
nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 946414-94-4
23
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 198153-51-4 5360545
24
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
25
Azathioprine Approved Phase 4 446-86-6 2265
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
27
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-67-6 938
28
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 98-92-0 936
29
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
30 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
31 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Endostatins Phase 4,Phase 2 71581480
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
40 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
41 interferons Phase 4,Phase 3,Phase 2,Phase 1
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
49 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Racepinephrine Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1739)
id Name Status NCT ID Phase
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
2 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4
3 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4
4 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4
5 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma Completed NCT00460798 Phase 4
6 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Completed NCT01339962 Phase 4
7 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
8 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4
9 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4
10 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4
11 Sorafenib in Elderly mRCC Completed NCT01728948 Phase 4
12 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
13 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4
14 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
15 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4
16 Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors Recruiting NCT02700568 Phase 4
17 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
18 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4
19 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Recruiting NCT01521715 Phase 4
20 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4
21 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4
22 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4
23 Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer Recruiting NCT02081755 Phase 4
24 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4
25 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Active, not recruiting NCT01266837 Phase 4
26 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4
27 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4
28 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4
29 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4
30 Cost Effectiveness Of Sunitinib In Central America And Caribbean Terminated NCT01033981 Phase 4
31 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Terminated NCT01073644 Phase 4
32 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4
33 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4
34 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4
35 Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load Terminated NCT00977054 Phase 4
36 Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Withdrawn NCT01353794 Phase 4
37 A Post Marketing Surveillance As Required By Philippine Food And Drug Administration Withdrawn NCT01781442 Phase 4
38 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
39 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3
40 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3
41 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3
42 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3
43 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3
44 Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery Unknown status NCT01936233 Phase 3
45 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3
46 A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy Unknown status NCT01560195 Phase 3
47 Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer Unknown status NCT00077220 Phase 3
48 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Unknown status NCT00227747 Phase 3
49 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3
50 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma

Genetic tests related to Renal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29
2 Renal Cell Carcinoma 29 24 HNF1A

Anatomical Context for Renal Cell Carcinoma

MalaCards organs/tissues related to Renal Cell Carcinoma:

39
Kidney, Endothelial, T Cells, Bone, Thyroid, Lung, Breast

Publications for Renal Cell Carcinoma

Articles related to Renal Cell Carcinoma:

(show top 50) (show all 5233)
id Title Authors Year
1
A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. ( 28512261 )
2017
2
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. ( 28089886 )
2017
3
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. ( 27939075 )
2017
4
RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. ( 28296677 )
2017
5
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. ( 28523933 )
2017
6
Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. ( 28523353 )
2017
7
Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. ( 28092369 )
2017
8
Periostin promotes migration and invasion of renal cell carcinoma through the integrin/focal adhesion kinase/c-Jun N-terminal kinase pathway. ( 28381189 )
2017
9
Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. ( 27638770 )
2017
10
High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. ( 28533485 )
2017
11
Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma. ( 27993630 )
2017
12
Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT. ( 28528853 )
2017
13
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. ( 28531203 )
2017
14
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. ( 28503240 )
2017
15
Abdominal seeding of renal cell carcinoma: radiologic, pathologic, and prognostic features. ( 28084547 )
2017
16
Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. ( 27923499 )
2017
17
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. ( 27841868 )
2017
18
Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. ( 27814278 )
2017
19
Downregulation of YAP in Clear Cell Renal Cell Carcinoma Contributes to Poor Prognosis and Progressive Features. ( 28249914 )
2017
20
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. ( 28205224 )
2017
21
Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. ( 28089832 )
2017
22
89Zr-bevacizumab PET: Potential Early Read Out for Efficacy of Everolimus in Metastatic Renal Cell Carcinoma Patients. ( 28082434 )
2017
23
FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. ( 27379982 )
2017
24
Image-guided ablation of renal cell carcinoma. ( 28527529 )
2017
25
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma. ( 28050950 )
2017
26
VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma. ( 28534376 )
2017
27
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. ( 28515811 )
2017
28
Benign MA1llerian Inclusions in Lymphadenectomies for Renal Cell Carcinoma: A Radiologic and Pathologic Mimic of Metastases. ( 28511950 )
2017
29
Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. ( 28081542 )
2017
30
Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. ( 28196407 )
2017
31
Strategies to overcome therapeutic resistance in renal cell carcinoma. ( 28089416 )
2017
32
Small (< 4 cm) Renal Tumors With Predominantly Low Signal Intensity on T2-Weighted Images: Differentiation of Minimal-Fat Angiomyolipoma From Renal Cell Carcinoma. ( 27824487 )
2017
33
Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer. ( 27983522 )
2017
34
Thrombus-like Tumor of Renal Cell Carcinoma Mimicking Transitional Cell Carcinoma of Kidney: A Case Report. ( 27896135 )
2017
35
High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition. ( 28030807 )
2017
36
Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis. ( 28112366 )
2017
37
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. ( 28532444 )
2017
38
Spinal analgesia improves surgical outcome after open nephrectomy for renal cell carcinoma: a randomized controlled study. ( 28532200 )
2017
39
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. ( 28522811 )
2017
40
Synchronous Presentation of Renal Cell Carcinoma and Hodgkin Lymphoma in an Adolescent. ( 28092312 )
2017
41
Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21a89cyclinA E2a89Bax/caspase-3 signaling pathway. ( 28184919 )
2017
42
Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3. ( 28288037 )
2017
43
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib. ( 28011500 )
2017
44
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. ( 28061437 )
2017
45
miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2. ( 27878305 )
2017
46
Prognostic Value of Inflammatory and Nutritional Scores in Renal Cell Carcinoma After Nephrectomy. ( 28528087 )
2017
47
Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. ( 28076721 )
2017
48
Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma. ( 28450954 )
2017
49
CA9 as a biomarker in preoperative biopsy of small solid renal masses for diagnosis of clear cell renal cell carcinoma. ( 27775441 )
2017
50
Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. ( 27864122 )
2017

Variations for Renal Cell Carcinoma

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma:

66
id Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 VHL p.Leu163Pro VAR_034998 rs28940297

ClinVar genetic disease variations for Renal Cell Carcinoma:

6 (show all 35)
id Gene Variation Type Significance SNP ID Assembly Location
1 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 GRCh37 Chromosome 3, 10191555: 10191555
2 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic/Likely pathogenic rs5030818 GRCh37 Chromosome 3, 10191488: 10191488
3 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic/Likely pathogenic rs5030820 GRCh37 Chromosome 3, 10191506: 10191506
4 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
5 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
6 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
9 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
10 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
11 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
12 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
13 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
14 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
15 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
16 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Pathogenic rs137853247 GRCh37 Chromosome 12, 121416663: 121416663
17 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
18 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
19 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
20 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
21 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh37 Chromosome 17, 7578508: 7578508
22 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
23 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
24 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
25 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
26 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
27 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
28 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
29 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387
30 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
32 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
33 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
34 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
35 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905

Cosmic variations for Renal Cell Carcinoma:

9 (show top 50) (show all 1232)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 48
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 48
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 48
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 48
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 48
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 48
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 48
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 48
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 48
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 48
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 48
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 48
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 48
14 COSM249389 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 31
15 COSM249350 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 31
16 COSM249348 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 31
17 COSM249454 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 31
18 COSM5012058 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 31
19 COSM30510 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 31
20 COSM5010682 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 31
21 COSM5013462 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 31
22 COSM5011020 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3322G>T p.D1108Y 31
23 COSM5014655 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 31
24 COSM5012645 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1218C>A p.F406L 31
25 COSM2888871 XKR7 kidney,NS,carcinoma,papillary renal cell carcinoma c.1409C>T p.T470M 31
26 COSM249421 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 31
27 COSM1272065 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.332C>A p.P111H 31
28 COSM20759 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 31
29 COSM30715 WISP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.868T>C p.C290R 31
30 COSM5012777 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 31
31 COSM249385 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 31
32 COSM249519 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 31
33 COSM26611 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860Y 31
34 COSM14400 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>T p.S65L 31
35 COSM30293 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.586A>T p.K196* 31
36 COSM17734 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.304C>G p.P102A 31
37 COSM36358 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-11T>A p.? 31
38 COSM17658 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 31
39 COSM34007 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.227T>C p.F76S 31
40 COSM249280 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.264G>A p.W88* 31
41 COSM18023 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.486C>G p.C162W 31
42 COSM17875 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.234T>G p.N78K 31
43 COSM30212 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.202T>C p.S68P 31
44 COSM18276 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.406T>G p.F136V 31
45 COSM14407 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>C p.V130L 31
46 COSM18212 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.491A>C p.Q164P 31
47 COSM14311 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.499C>T p.R167W 31
48 COSM14380 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.548C>A p.S183* 31
49 COSM30295 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.341-2A>G p.? 31
50 COSM18015 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 31

Copy number variations for Renal Cell Carcinoma from CNVD:

7 (show top 50) (show all 1298)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma patients vs. healthy controls: 35 (show top 50) (show all 278)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SLC12A1 solute carrier family 12 (sodium/potassium/chloride transporter), member 1 Kidney - 9.35 0.000
2 CALB1 calbindin 1, 28kDa Kidney - 8.95 0.000
3 FXYD4 FXYD domain containing ion transport regulator 4 Kidney - 8.29 0.000
4 CLDN8 claudin 8 Kidney - 8.20 0.000
5 KCNJ1 potassium channel, inwardly rectifying subfamily J, member 1 Kidney - 8.20 0.000
6 NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) Kidney - 8.18 0.000
7 MUC15 mucin 15, cell surface associated Kidney - 7.96 0.000
8 SCNN1G sodium channel, non voltage gated 1 gamma subunit Kidney - 7.91 0.000
9 HPD 4-hydroxyphenylpyruvate dioxygenase Kidney - 7.78 0.000
10 FABP1 fatty acid binding protein 1, liver Kidney - 7.74 0.000
11 DNASE1 deoxyribonuclease I Kidney - 7.59 0.000
12 SLC7A13 solute carrier family 7 (anionic amino acid transporter), member 13 Kidney - 7.29 0.000
13 ANGPTL4 angiopoietin-like 4 Kidney + 7.25 0.000
14 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 Kidney + 7.16 0.000
15 ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 Kidney - 7.13 0.000
16 PCP4 Purkinje cell protein 4 Kidney - 7.13 0.000
17 KNG1 kininogen 1 Kidney - 7.12 0.000
18 TYRP1 tyrosinase-related protein 1 Kidney - 7.10 0.000
19 FGF9 fibroblast growth factor 9 Kidney - 6.99 0.000
20 EGF epidermal growth factor Kidney - 6.92 0.000
21 RALYL RALY RNA binding protein-like Kidney - 6.81 0.000
22 PVALB parvalbumin Kidney - 6.73 0.000
23 KCNJ10 potassium channel, inwardly rectifying subfamily J, member 10 Kidney - 6.69 0.000
24 TMEM213 transmembrane protein 213 Kidney - 6.64 0.000
25 SLC22A8 solute carrier family 22 (organic anion transporter), member 8 Kidney - 6.58 0.000
26 IRX2 iroquois homeobox 2 Kidney - 6.56 0.000
27 SLC26A7 solute carrier family 26 (anion exchanger), member 7 Kidney - 6.56 0.000
28 SLC4A1 solute carrier family 4 (anion exchanger), member 1 (Diego blood group) Kidney - 6.53 0.000
29 GPC5 glypican 5 Kidney - 6.53 0.000
30 RHCG Rh family, C glycoprotein Kidney - 6.52 0.000
31 SOST sclerostin Kidney - 6.51 0.000
32 SFRP1 secreted frizzled-related protein 1 Kidney - 6.49 0.000
33 HEPACAM2 HEPACAM family member 2 Kidney - 6.45 0.000
34 NELL1 neural EGFL like 1 Kidney - 6.38 0.000
35 SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 Kidney - 6.34 0.000
36 RAB25 RAB25, member RAS oncogene family Kidney - 6.32 0.000
37 TMPRSS2 transmembrane protease, serine 2 Kidney - 6.31 0.000
38 TMEM52B transmembrane protein 52B Kidney - 6.28 0.000
39 ERBB4 erb-b2 receptor tyrosine kinase 4 Kidney - 6.26 0.000
40 SOSTDC1 sclerostin domain containing 1 Kidney - 6.25 0.000
41 SH3GL2 SH3-domain GRB2-like 2 Kidney - 6.16 0.000
42 ALDOB aldolase B, fructose-bisphosphate Kidney - 6.13 0.003
43 APOC1 apolipoprotein C-I Kidney + 6.11 0.000
44 UMOD uromodulin Kidney - 6.07 0.000
45 NPTX2 neuronal pentraxin II Kidney + 6.05 0.000
46 LOC284578 uncharacterized LOC284578 Kidney - 6.02 0.000
47 ESRRB estrogen-related receptor beta Kidney - 5.99 0.000
48 SLC13A3 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 Kidney - 5.96 0.001
49 TSPAN8 tetraspanin 8 Kidney - 5.96 0.000
50 WNK4 WNK lysine deficient protein kinase 4 Kidney - 5.94 0.000
Search GEO for disease gene expression data for Renal Cell Carcinoma.

Pathways for Renal Cell Carcinoma

Pathways related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1 12.23 EPAS1 FH HIF1A MET VEGFA VHL
2 12.01 CA9 EPAS1 FLCN HIF1A
3
Show member pathways
11.86 EPAS1 FH FLCN HIF1A MET VEGFA
4 11.68 HIF1A VEGFA VHL
5
Show member pathways
11.52 EPAS1 HIF1A VEGFA VHL
6 11.45 CA9 HIF1A VEGFA
7 11.31 HIF1A VEGFA VHL
8 11.25 HIF1A HNF1A VEGFA
9 11.03 EPAS1 VEGFA VHL
10 10.67 HIF1A VHL
11 10.43 HIF1A VEGFA
12 10.36 EPAS1 VEGFA VHL

GO Terms for Renal Cell Carcinoma

Cellular components related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.92 EPAS1 HIF1A HNF1A HNF1B

Biological processes related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.93 HIF1A HNF1A HNF1B TFE3 VHL
2 negative regulation of apoptotic process GO:0043066 9.85 HIF1A HNF1B IL2 OGG1 VEGFA VHL
3 cellular response to hypoxia GO:0071456 9.7 EPAS1 HIF1A VEGFA
4 positive regulation of cell adhesion GO:0045785 9.61 FLCN TFE3 VEGFA
5 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.61 EPAS1 FLCN HIF1A HNF1A HNF1B IL2
6 camera-type eye morphogenesis GO:0048593 9.56 HIF1A VEGFA
7 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.51 HIF1A VEGFA
8 branching morphogenesis of an epithelial tube GO:0048754 9.5 HNF1B MET VEGFA
9 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 9.49 HNF1A HNF1B
10 surfactant homeostasis GO:0043129 9.48 EPAS1 VEGFA
11 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.46 EPAS1 HIF1A
12 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.4 HIF1A VEGFA
13 negative regulation of Rho protein signal transduction GO:0035024 9.33 FLCN KANK1 MET
14 regulation of pronephros size GO:0035565 9.26 HNF1A HNF1B
15 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 CA9 EPAS1 HIF1A VEGFA VHL
16 regulation of transcription, DNA-templated GO:0006355 10.2 EPAS1 FHIT HIF1A HNF1A HNF1B KANK1

Molecular functions related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.56 EPAS1 HIF1A HNF1A VHL
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.46 EPAS1 HIF1A HNF1A TFE3
3 protein heterodimerization activity GO:0046982 9.35 EPAS1 HIF1A HNF1A HNF1B VEGFA
4 protein dimerization activity GO:0046983 8.92 EPAS1 HIF1A HNF1A TFE3

Sources for Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....